

DEC. 23. 2002^{pl} 11:09AM ^{aside this} JENKINS & WILSON

NO. 088 PTO/P. 6, (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/750,609
Filing Date	12/28/2000
First Named Inventor	David Robertson
Group Art Unit	
Examiner Name	
Attorney Docket Number	1242/27/2/2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Prebha Chundani

Date Considered

12/23/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/750,609
		Filing Date	12/28/2000
		First Named Inventor	David Robertson
		Group Art Unit	
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	1242/27/2/2	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gpc	C1	FLATTEM ET AL., "Identification of a Coding Mutation in the Norepinephrine Transporter Gene Which Predisposes a Family to Orthostatic Intolerance," Am. J. Human Genet., Vol. 65 (No. 4), p. A43, (1999).	X
	C2	SHANNON, "Functional Polymorphism of the Norepinephrine Transporter (NET) Presenting as Mitral Valve Prolapse and Orthostatic Intolerance," Circulation, Vol. 110 (No. 18), p. I.195, (November 2, 1999).	X
	C3	OWEN ET AL., "Norepinephrine Transporter Gene Polymorphism is not Associated with Susceptibility to Major Depression," Psychiatry Research, Vol. 87 (No. 1), p. 1-5, (1999).	X
	C4	PACHOLCZYK ET AL., "Expression Cloning of a Cocaine and Antidepressant-Sensitive Human Noradrenaline Transporter," BioNature, p. 350-353, (March 28, 1991).	X
	C5	PORZGEN ET AL., "Molecular Cloning and Organization of the Coding region of the Human Norepinephrine Transporter Gene," Biochem. Biophys. Res. Commun., Vol. 215 (No. 3), p. 1145-1150, (October 24, 1995).	X
	C6	WANG ET AL., "Genetic Approaches to Studying Norepinephrine Function: Knockout of the Mouse Norepinephrine Transporter," Gene Biol. Psychiatry, p. 1124-1130, (1999).	X
	C7	ANONYMOUS, "Gene Characterization Kits," In: Stratagene Catalog, p. 39, (1988).	X
	C8	PCT International Search Report for PCT International Application No. PCT/US00/35491.	
	C9	JORDAN ET AL., "Contrasting Actions of Pressor Agents in Severe Autonomic Failure," Am. J. Med., Vol. 105 (No. 2), p. 116-124, (1998). (Abstract only)	X
	C10	CHOY ET AL., "Abnormalities of the QT Intercal in Primary Disorders of Autonomic Failure," Am. Heart J., Vol. 136 (No. 4), p. 664-671, (1998). (Abstract only)	X
✓	C11	JORDAN ET AL., "Contrasting Effects of Vasodilators on Blood Pressure and Sodium Balance in the Hypertension of Autonomic Failure," J. Am. Soc. Nephrol., Vol. 10 (No. 1), p. 35-42, (1999). (Abstract only)	X

Examiner Signature	Prabha Chunduru	Date Considered	12/23/02
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC. 23. 2002 11:10AM

JENKINS & WILSON

NO. 088-TO/SE P. 8 (10-96)

Please type a plus sign (+) inside this box

+

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/750,609
		Filing Date	12/28/2000
		First Named Inventor	David Robertson
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	1242/27/2/2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	C12	JACOB ET AL., "Effects of Standing on Cerebrovascular Resistance in patients with Idiopathic Orthostatic Intolerance," Am. J. Med., Vol. 106 (No. 1), p. 59-64, (1999). (Abstract only)	X
	C13	GILMAN ET AL., "Consensus Statement on the Diagnosis of Multiple System Atrophy," J. Neurol. Sci., Vol. 163 (No. 1), p. 94-98, (February 1, 1999). (Abstract only)	X
	C14	SHANNON ET AL., "Acute Effect of Ephedrine on 24-h Energy Balance," Clin. Sci. (Colch), Vol. 96 (No. 5), p. 483-491, (1999). (Abstract only)	X
	C15	JACOB ET AL., "Abnormal Norepinephrine Clearance and Adrenergic Receptor Sensitivity in Idiopathic Orthostatic Intolerance," Circulation, Vol. 99 (No. 13), p. 1706-1712, (April 6, 1999). (Abstract only)	X
	C16	ROBERTSON ET AL., "Neurally Mediated Syncope: Pathophysiology and Implications for Treatment," Am. J. Med. Sci., Vol. 317 (No. 2), p. 102-109, (1999). (Abstract only)	X
	C17	AUSTIN ET AL., "Multiple System Atrophy: Clinical Presentation and Diagnosis," Tenn. Med., Vol. 92 (No. 2), p. 55-57, (1999). (Abstract only)	X
	C18	FURLAN ET AL., "Chronic Orthostatic Intolerance: a Disorder with Discordant Cardiac and Vascular Sympathetic Control," Circulation, Vol. 98 (No. 20), p. 2154-2159, (November 17, 1998). (Abstract only)	X
	C19	ROBERTSON, "Distribution and Observed Associations of Orthostatic Blood Pressure Changes in Elderly General Medicine Outpatients," Am. J. Med. Sci., Vol. 315 (No. 5), p. 287-295, (1998). (Abstract only)	X
	C20	CASWELL, "Orthostatic Intolerance," NASA West Virginia Space Grant Consortium, (1997).	
	C21	"Chronic Orthostatic Intolerance (COI) Nerve Abnormality," Causes Disabling Rapid Heart Rate, Dizziness, Dallas, Texas, (November 17, 1998).	
V	C22	NATIONAL DYSAUTONOMIA RESEARCH FOUNDATION, "Orthostatic Intolerance Syndromes," (1997).	

Examiner Signature	Prabha Chenduru	Date Considered	12/23/02
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Received from <9194190383> at 12/23/02 11:14:40 AM [Eastern Standard Time]